Sign in
Enrolling by invitationPhase 1

Long-term safety follow-up of people treated with ADP cell therapy for cancer

Tracks long-term safety of people who received ADP cell therapy for cancer.

Key facts

Who runs it
USWM CT, LLC
Where
London, Manchester, and Sutton, United KingdomSee the 3 sitesAlso in 7 other countries, 21 sites
Trial code
Registry title
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
Status
Enrolling by invitation
Phase
Phase 1
People taking part
250 people, planned
Started
9 Apr 2018
Expected to end
1 Apr 2032
Type of study
Interventional
Treatments tested
  • ADP adoptive cell therapy
Record updated
11 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people who already received ADP adoptive cell therapy. It follows their long-term safety for up to 15 years after the last infusion.

Sex
All sexes can join.
Earlier treatment
People must have had at least one dose of ADP adoptive cell therapy. They must have finished or left an ADP-sponsored or supported study, or finished treatment through managed access to a GSK adoptive cell therapy.

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Participants who have received at least one dose of ADP adoptive cell therapy agent
  • Participants who have completed ADP sponsored or supported interventional study or have withdrawn from it
  • Participants who have completed treatment as part of managed access to a GSK adoptive cell therapy
  • Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
  • The investigator is responsible for review of medical history
  • Capable of giving signed informed consent

Who cannot take part

  • None

Where in United Kingdom

Also in 7 other countries, 21 sites

  • University College London Hospitals NHS Foundation TrustLondon, United KingdomEnrolling by invitation
  • ManchesterHospital not named in the registryEnrolling by invitation
  • The Royal Marsden NHS Foundation TrustSutton, United KingdomEnrolling by invitation

About the trial

What the trial wants to find out

This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.

The group in the trial

  • Participants receiving ADP adoptive cell therapyTreatment being tested

    Treatment: ADP adoptive cell therapy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Long-Term Follow-Up (LTFU) of Participants Treated With ADP Adoptive Cell Therapies
Plain-language title
Long-term safety follow-up of people treated with ADP cell therapy for cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
11 August 2026